

WORLD **VACCINE &**  
 **IMMUNOTHERAPY**

CONGRESS  
WEST COAST

**2–5 December 2019**  
San Francisco Airport Marriott Waterfront

---

Integrating the  
technologies  
revolutionising  
immunotherapy  
and its impact  
on vaccines  
development

---

PART OF

CREATED BY

SPARKSOMETHING

**TERRAPINN** 

WORLD **VACCINE**  
 WASHINGTON

WORLD **VACCINE**  
 EUROPE

[www.terrappinn.com/wvc-west-coast](http://www.terrappinn.com/wvc-west-coast)

## Scientific Advisory Board



**DR THERESA LAVALLEE**

Vice President, Translational Medicine  
**Parker Institute for Cancer  
Immunotherapy**



**DR BIOL. SCI. ALESSANDRO SETTE**

Center Head, Division Head, and  
Professor Center for Infectious Disease,  
**La Jolla Institute**



**DR PETER HOTEZ,**

Dean of National School of Tropical  
Medicine, Director, Texas Children's  
Hospital Center **Baylor College of  
Medicine**



**DR JERALD SADOFF,**

Senior Advisor, **Janssen Infectious  
Diseases and Vaccines**



**DR ROY BAYNES,**

Senior Vice President Global Clinical  
Development and Chief Medical Officer,  
**Merck Research Laboratories**



**DR KARIN JOOSS,**

Executive Vice President of Research,  
and Chief Scientific Officer, **Gritstone  
Oncology**



**DR STEVEN TOWNSON,**

Senior Principal Scientist, Early Oncology  
Development, **Merck Research  
Laboratories**



**PROF BALI PULENDRAN,**

Professor in the Department of Pathology  
and Laboratory Medicine, **Stanford  
University School of Medicine**



**DR MARIA KARASARIDES,**

Executive Director, ImmunoOncology,  
**Regeneron Pharmaceuticals**



**DR EZRA COHEN,**

Professor of Medicine, **UC San Diego Moores  
Cancer Center**, Co-Director, **San Diego Center  
for Precision Immunotherapy**



**DR. WAYNE C. KOFF,**

President and CEO, **The Human  
Vaccines Project**

## Confirmed Speakers

- *Dr Evanthia Galanis, Chair Molecular Medicine, Professor of Oncology, Mayo Clinic*
- *Dr Ignacio Wistuba, Professor & Chair, Department of Translational Molecular Pathology, MD Anderson Cancer Center*
- *Dr Ezra Cohen, Professor of Medicine, UCSD Moores Cancer Center, Co-director, San Diego Center for Precision Immunotherapy*
- *Dr Sean Tucker, CSO and Vice President Research, Vaxart*
- *Dr. Steven Townson, Senior Principal Scientist, Early Oncology Development, Merck Research Laboratories*
- *Dr Peter Hotez, President of the Sabin Vaccine Institute & Dean of National School of Tropical Medicine, Baylor College of Medicine*
- *Dr Rachel Clemens, Commercial Innovation Manager, Center for the Advancement of Science in Space*
- *Dr Susan Old, Acting Deputy Director, NIAID*
- *Dr Vu Truong, Chief Executive Officer and Chief Scientific Officer, Aridis Pharmaceuticals*
- *Dr Maria Karasarides, Executive Director, Immuno-Oncology, Regeneron Pharmaceuticals*
- *Rajeev Dadoo, Partner, SR One*
- *Mary Jo Potter, CEO and Managing Director, Healthcare Angels*
- *Dr Kathrin Janssen, SVP, Head of Vaccine Research & Development, Pfizer*
- *Dr Alexander Kort, Senior Vice President Corporate Development, Themis Bioscience GmbH Themis*
- *Dr Biol. Sci. Alex Sette Center Head, Division Head, and Professor, Center for Infectious Disease, La Jolla Institute for Immunology*
- *Dr Kirsteen Maclean, PhD., Associate, Scientific Director, Biomarker & Translational Strategy Definiens*
- *Dr Robert Hollingsworth, Vice President & CSO Cancer Vaccines, Pfizer*
- *Dr Steven Reed, Founder, Distinguished Scientist, IDRI*
- *Dr Pravin Kaumaya, Professor, Director, Div. Vaccine Res & Peptide/Protein Engineering laboratory, The Ohio State University College of Medicine*
- *Michael Murray, Analyst, Biotechnology Value Fund*
- *Dr Gary Starling, Associate Vice President, Protein Science, Merck*
- *Dr Hanspeter Gerber, CSO, 3T Biosciences*
- *Dr Stephen Schoenberger, Center Head; Professor, Division of Developmental Immunology, LaJolla Institute for Immunology*
- *Dr Raymond Tesi, Co-Founder, President & CEO, INmune Bio*
- *Dr Roland Dunbrack, Director, Molecular Modeling Facility, Fox Chase Cancer Center*
- *Dr Vadim Klyushnichenko, Vice President of Pharmaceutical Development & Quality, Calibr – A division of Scripps Research*
- *Dr Mike Schopperle, CEO, CureMeta LLC.*
- *Dr Martin Moore, Co-Founder & CEO, Meissa Vaccines*
- *Chester Kitchen, Cancer Patient Advocate*
- *Dr Jeffrey Froude, Major, Stm, Vaccines/Therapeutics Division, Defense Threat Reduction Agency*
- *Dr Lesley Stolz, EVP & Chief Business Officer, Annexon Biosciences*
- *Dr Raphael Rousseau, EVP, Head of Product Development, CMO, Gritstone Oncology*
- *Dr Andrew Lees, Scientific Director, Fina Biosolutions*
- *Javad M. Aman, President and CSO, Integrated Biotherapeutics*
- *Dr Sangeeta Tiwari, Associate (faculty), Albert Einstein College of Medicine*

# Confirmed Speakers

- *Dr Louis-Philippe Vézina, PhD, CEO, Angany Inc.*
- *Dr Nancy Sullivan, Chief and Biodefense Research Section, Vaccine Research Center National Institutes of Health*
- *Jan Poolman, Head Bacterial Vaccine Discovery and Early Development, Janssen*
- *Dr Jerald Sadoff, Senior Advisor Vaccine Development, Janssen Infectious Diseases and Vaccines*
- *Dr Kalpit Vora, Director, infectious disease and Vaccine Basic Research, Merck*
- *Dr Chia-Wei Tsai, Branch Chief, Antiviral and Antitoxin programs, BARDA*
- *Dr. Sina Bavari, Science Director, US Army Medical Research Institute of Infectious Diseases, USAMRIID*
- *Dr Richard Scheuermann, Director, La Jolla Campus, J. Craig Venter Institute*
- *Dr Nabil Al Humadi, Pharmacologist and Toxicologist, Food and Drug Administration*
- *Dr Clemencia Pinilla, Associate Member, Torrey Pines Institute for Molecular Studies*
- *Dr Duncan Mwangi, Research Director, Zoetis*
- *Dr Darrick Carter, Vice President - Adjuvant Technology, IDRI*
- *Dr Leonard Friedland, Vice President, Scientific Affairs and Public Health Vaccines, North America, GSK*
- *Dr Jun Tang, Senior Manager, CRI Venture Fund and Clinical Accelerator, Cancer Research Institute*
- *Dr Larry Zeitlin, President, Mapp Biopharmaceutical, Inc*
- *Dr Julia Spencer, Associate Vice President, Global Vaccine Public Policy, Partnerships, Merck*
- *Dr Steven Kleiboeker, Vice President, Research & Development, Viracor Eurofins BioPharma Services*
- *Dr Tom Davis, CMO, Genocera*
- *Professor Bali Pulendran, Professor in the Department of Pathology and Laboratory Medicine, Stanford University School of Medicine*
- *Dr Beckie Ingram, Principal Investigator, Queens University Belfast*
- *Dr Bruce Keyt, CSO, IGM Biosciences*
- *Dr Alexander Koglin, PhD, Co-founder, Chief Science and Technology Officer, NTxBIO*
- *Dr Ofer Levy, Director, Precision Vaccines Program, Boston Children's Hospital & Professor, Harvard Medical School*
- *Dr Hasan Jafri, Senior Director, Clinical Research and Development, Infectious Disease and Vaccines, MedImmune*
- *Dr Praveen Bommareddy, Translational Research Lead, Replimmune*
- *Dr Wouter Hazenbos, Scientist, Genentech*
- *Dr Kevin Killeen, Chief Scientific Officer, Matrivax*
- *Dr Naik Rumi Armaghan, Ph.D., Director and Head of Design Sciences in FluNXT, Sanofi Pasteur's "Biotech-lite"*
- *Dr Sean Bennett, Senior Director, Clinical Development and Medical Affairs, Emergent BioSolutions*
- *Sarah Royalty Tredo, Senior Director, Emergent Biosolutions*
- *Dr Helen Sabzevari, President, Precigen*
- *Charles Heffernan, Member, BioPhorum Operations Group; Director, CRB*
- *Dr Justin Moran, Senior Director Bioprocess Development, Pfizer*
- *Dr Lakshmi Khandke, Senior Program Advisor, Center for Vaccine Innovation & Access, PATH*
- *Dr Karen Aboody, Professor, Department of Developmental & Stem Cell Biology and Division of Neurosurgery, City of Hope; Founder & CSO, TheraBiologics*
- *Dr Michael J. Mitchell, Ph.D., Skirkanich Assistant Professor of Innovation, Department of Bioengineering, University of Pennsylvania*
- *Dr Aubree Gordon, Associate Professor of Epidemiology, University of Michigan*

# Confirmed Speakers

- *Dr Jason Comer, Assistant Professor, Department of Microbiology and Immunology, University of Texas Medical Branch at Galveston*
- *Dr John Ross, Vice President, Protein Therapeutics, Cue Biopharma*
- *Dr Chris Clegg, President, Founder & CSO, TRIA Bioscience*
- *Dr William Smith, Chief Executive Officer, Alliance for Multispecialty Research LLC*
- *Dr Timothy Cooke, CEO and Board member, NovaDigm Therapeutics*
- *Dr I-Ming Wang, Director, Translational Oncology, Pfizer*
- *Dr Mary Redman, Associate Member, Clinical Research Division, Fred Hutchinson Cancer Research Center*
- *Dr David Canton, Director, R&D and Clinical Science, OncoSec*
- *Dr Jon Wigginton, SVP, Clinical Development & Chief Medical Officer, MacroGenics*
- *Dr Bruno Anspach, Director of Clinical Operations Latin America - vaccines, GSK*
- *Dr Joseph Kim, Chief Executive Officer, Inovio Pharmaceuticals*
- *Dr Brian Price, COO, Blue Water Vaccines, Inc*
- *Dr Craig Thomson, CSO, Blue Water Vaccines, Inc*
- *Dr Willem Hanekom, Deputy Director, TB Vaccines, Bill & Melinda Gates Foundation*
- *Dr Eric Appel, Assistant Professor of Material Science and Engineering, Stanford University*
- *Dr Ali Harandi, Lab head, Dpt of Microbiology & Immunology, University of Gothenburg*
- *Dr Timothy W Phares, Head of Immunology, Explorations in Global Health (ExGloH), Leidos*
- *Dr Maureen Bruhns, Senior Director of Analytical Development, Sutro Bio*
- *Dr Jo Anne Welsch, Scientific Director, Group B Streptococcal Vaccine Project, PATH*
- *Dr Ovid Trifan, CMO & SVP Clinical Development, Apexigen*
- *Dr William Heath, Professor, University of Melbourne, Scientific Advisor, Avalia Immunotherapies Limited*
- *Dr Mark Davis, Professor, Microbiology & Immunology, Director, Stanford Institute for Immunity, Transplantation and Infection, Stanford University School of Medicine*
- *Dr Kyle Smith, PhD, Director, Research and Development, Micromedex*
- *Dr Tony Reid, CSO, EpicentRx*
- *Dr Andreas Niethammer, Senior Vice President, Head of Clinical Development Immunotherapy for Solid Tumors, Sorrento Therapeutics*
- *Dr Theresa LaVallee, Vice President, Translational Medicine, Parker Institute for Cancer Immunotherapy*
- *Dr Martina Sersch, CMO, Mustang Bio*
- *Dr Angelos Stergiou, CEO, SELLAS*
- *Dr Stephen Nagler, Executive Director, MedPro Investors*
- *Dr Vanessa Jonsson, Assistant Research Professor, City of Hope*
- *Seth Bannon, Founding Partner, Fifty Years*
- *Dr Jennifer Cochran, Chief Scientist, Lagunita Biosciences*
- *Dr Wouter Meuleman, Director, Venture Investments, Illumina Ventures*
- *Dr Farshad Guirakhoo, CSO, GeoVax*
- *Dr Bitu Sahaf, Senior Research Scientist; Center for Cancer Cell Therapy, Stanford Cancer Institute; Technical Director, Stanford Cancer Correlative Science Unit (CCSU); Correlatives for Parker Institute for Immunotherapy; Scientific Director, Stanford CIMAC*
- *Dr Adil Daud, Clinical Professor of Medicine, Director, Melanoma Clinical Research, UCSF Helen Diller Family Comprehensive Cancer Center*
- *Dr Pralay Mukhopadhyay, Head of Late stage IO, Oncology Biometrics, AstraZeneca*
- *Dr David Whitacre, Senior Vice President, VLP Biotech*

## Confirmed Speakers

- *Dr Lacey Kitch, Director, Informatics at Parker Institute for Cancer Immunotherapy*
- *Dr Nancy Whiting, Senior Vice President, Development, Seattle Genetics*
- *Dr Xiaoping Zhu, Interim Associate Dean & Department Chair, University of Maryland*
- *Dr Grace Chen, Deputy Chief of The Clinical Trials Program in the VRC, NIH*
- *Dr Sari Pesonen, Vice President Scientific And Clinical Development, Co-Founder, Valo Therapeutics*
- *Dr Francesca Milletti, Associate Director Translational Medicine, Kite, a Gilead Company*
- *Dr Trevor Clancy, Chief Scientific Officer, NEC Oncolmmunity AS*
- *Dr Mike Stebbins, MCDC Executive Director, Medical CBRN Defense Consortium (MCDC)*
- *Dr James Wassil, Vice President and GH&V BU Head, Vaccines, Pfizer*
- *Dr Juan Salazar, Executive Vice President, Connecticut Children's Medical Center*
- *Dr Sujan Shrestha, Associate Professor, La Jolla Institute for Immunology*
- *Dr Lauren Wood, CMO, PDS Biotechnology*
- *Dr Bruce Y. Lee, Professor of Health Policy and Management, City University of New York (CUNY), Exec Director of PHICOR, CEO of Symsilico, & Senior Contributor, Forbes*
- *Dr Heidi Zhang, Global Head Analytical Development Cell Therapy, Juno Therapeutics, A Celgene Company*
- *Dr Daryl Drummond, Biotechnology Consultant*
- *Dr Wen Bo Wang, SVP, Technical Operations, Fate Therapeutics*
- *Dr Meghna Das Thakur, Biomarker Lead, T-Cell BiSpecifics, Genentech*
- *Dr Jimmy Linn, CSO, Freenome*
- *Dr Pamela D. Garzone, Chief Medical Officer, Calibr, a division of Scripps Research*
- *Dr Stuart Abbot, CSO, Adicet Bio, Inc*
- *Dr Lenny Moise, Director of Vaccine Research, EpiVax Inc*
- *Dr Patrick Daugherty, CSO and Founder, Serimmune*
- *Dr Anders Lilja, SVP Technical Development, HOOKIPA Pharma*
- *Dr Krishna Prasad, Founder, Citranvi*
- *Dr Risat Jannat, Director, Global Vaccines & Biologics Commercialization, Merck & Co.*
- *Dr Daniel R. Henderson, Ph.D., CEO, CSO, Verndari, Inc. \*TBC*
- *Christa Pawlowski, Project Operations Director, SapVax LLC*
- *Dr Victor Defilippis, Associate Professor, Oregon Health and Science*
- *Dr Kena Swanson, Director, Viral Vaccines, Pfizer Vaccine Research & Development*
- *Dr Hong Jin, Senior Director, Fellow R&D - Clinical Pharmacology & Safety Sciences, AstraZeneca*

# Pre-Congress Workshops

Monday 2<sup>nd</sup> December

*Choose from either Workshop A or B:*

	WORKSHOP A	WORKSHOP B
1:00	<p><b>Workshop Leader's opening remarks:</b></p> <p><b>Uses and clinical application of immune profiling assays for cancer:</b>  <i>The use of novel assays and computational methods to analyze the immune system is a very fast-moving field and it is challenging to keep up with the pace of change. Join our Advances in Immune Profiling Assays workshop on 2<sup>nd</sup> December for an in depth look at the uses and clinical application of new methods to characterize and profile the human immune system for the accelerated development of new therapies.</i></p> <p><b>Topics:</b></p> <ul style="list-style-type: none"> <li>• Assessing base-line immune function</li> <li>• Assessing predictive biomarkers for PD1 / PDL1 immunotherapies</li> <li>• How to assess the efficacy and longevity of cellular therapies</li> <li>• Assessing the tumor microenvironment</li> <li>• Discovery of genomic predictors and genomic alterations that promote or suppress immune response</li> <li>• Discovery and development of novel biomarkers</li> </ul> <p><b>Dr Ignacio Wistuba</b>, Professor &amp; Chair, Department of Translational Molecular Pathology, <b>MD Anderson Cancer Center</b></p> <p><b>Dr I-Ming Wang</b>, Director, Translational Oncology, <b>Pfizer</b></p> <p><b>Dr Mark Davis</b>, Professor, Microbiology &amp; Immunology, Director, Stanford Institute for Immunity, Transplantation and Infection, <b>Stanford University School of Medicine</b></p> <p><b>Dr Vanessa Jonsson</b>, Assistant Research Professor, <b>City of Hope</b></p> <p><b>Dr Bitu Sahaf</b>, Senior Research Scientist; <b>Stanford Cancer Institute</b>; Technical Director, <b>PICI Cancer Correlative Science Unit</b></p> <p><b>Dr Meghna Das Thakur</b>, Biomarker Lead, T-Cell BiSpecifics, <b>Genentech</b></p>	<p><b>Workshop Leader's opening remarks:</b></p> <p><b>Advances in adjuvant technology for vaccines:</b>  <i>Vaccine adjuvants have been used successfully for decades to enhance the ability to provoke an immune response of weak antigens and improve the overall potency of vaccines. Join this workshop to explore the latest advances in novel adjuvant technology for vaccines, the value of current adjuvants and how to improve them.</i></p> <p><b>Topics:</b></p> <ul style="list-style-type: none"> <li>• Adjuvant technology and its impact on vaccine development</li> <li>• Use of receptor agonists in improving existing adjuvants or designing new novel adjuvants for different animal species</li> <li>• Precision adjuvants; tailoring immune activation for next generation vaccines</li> <li>• Evaluation of Human Vaccines prior Vaccination: Of Hope and Hype</li> <li>• Can next generation adjuvants break tolerance to assist in immune oncology?</li> <li>• Deploying adjuvants for special populations</li> <li>• Combination adjuvants – how should they be designed and what are the risks</li> <li>• Adjuvating live vaccines</li> </ul> <p><b>Dr Darrick Carter</b>, Vice President - Adjuvant Technology, <b>IDRI</b></p> <p><b>Dr Duncan Mwangi</b>, Research Director, <b>Zoetis</b></p> <p><b>Dr Ofer Levy</b>, Director, Precision Vaccines Program, Boston Children's Hospital &amp; Professor, <b>Harvard Medical School</b></p> <p><b>Ali Harandi</b>, Lab head, Dpt of Microbiology &amp; Immunology, <b>University of Gothenburg</b></p> <p><b>Dr Victor Defilippis</b>, Associate Professor, <b>Oregon Health and Science</b></p> <p><b>Dennis Carson</b>, Professor Emeritus, Medicine, <b>UC San Diego – invited</b></p> <p><i>Additional speakers TBC</i></p>
5:00	<b>Chair's closing remarks and end of workshop</b>	

# Main Agenda

Day 1 – Tuesday 3<sup>rd</sup> December

Day 1 Keynote Plenary Sessions				
08.20	Chair's Opening Remarks			
08.30	<p>Immunotherapy 2020 and beyond – what are the next frontiers?</p> <ul style="list-style-type: none"> <li>In the last 10 years ground breaking advances and progress have been made in the treatment of cancer with immunotherapy-based approaches.</li> <li>We have seen approvals of cancer vaccines, multiple single agent and combination checkpoint inhibitor agents in a broad range of tumor types, tissue-agnostic immunotherapy and cellular and gene therapies.</li> <li>These agents are improving survival and providing cures in some cancer patients.</li> <li>Several new immunotherapy advancements, opportunities and challenges are on the horizon.</li> </ul> <p>Dr Theresa LaVallee, Vice President, Translational Medicine, Parker Institute for Cancer Immunotherapy</p>			
08:50	<p>Advances in single cell sequencing and combination of multiple omics data for developing a better understanding of response to immunotherapy and vaccines</p> <p>Dr Richard Scheuermann, Director, La Jolla Campus, J. Craig Venter Institute Dr Lacey Kitch, Director, Informatics, Parker Institute for Cancer Immunotherapy</p>			
09.45	<p>The use of vaccines and antibodies in biodefense strategies to combat emerging threats</p> <p>Jeffrey Froude, Major, Stm, Vaccines/Therapeutics Division, Defense Threat Reduction Agency Chia-Wei Tsai, Branch Chief, Antiviral and Antitoxin programs, BARDA Dr. Sina Bavari, Science Director, US Army Medical Research Institute of Infectious Diseases, USAMRIID William Dowling, Microbiologist Science and Technology Manager, Defense Threat Reduction Agency – invited</p>			
10.30	<p><b>Morning Networking Break</b></p> <p><i>Meet the Investor Speed Networking: Meet, exchange interests and swap business cards with investors in the biotechnology sector. A great opportunity to maximize your time at the event and meet up to 10 investors in 15mins.</i></p> <p><i>Confirmed investors include;</i></p> <p><i>Michael Murray, Analyst, Biotechnology Value Fund</i> <i>Mary Jo Potter, Founder and CEO, Healthcare Angels</i> <i>Rajeev Dadoo, Partner, SR One</i> <i>Dr Wouter Meuleman, Director, Venture Investments, Illumina Ventures</i> <i>Dr Stephen Nagler, Executive Director, MedPro Investors</i> <i>Seth Bannon, Founding Partner, Fifty Years</i> <i>Dr Jennifer Cochran, Chief Scientist, Lagunita Biosciences</i></p> <p><i>Additional Investors TBC</i></p>			
	Immune Profiling	Cancer Immunotherapy	New Technology	Vaccine Development
11.30	Chair's Opening Remarks	Chair's Opening Remarks: Dr Robert Hollingsworth, Vice President & CSO Cancer Vaccines, Pfizer	Chair's Opening Remarks Dr Lesley Stolz, EVP & Chief Business Officer, Annexon Biosciences	Chair's Opening Remarks Erin Duffy, PHD Chief of Research & Development, CARB-X – invited
11.40	Immuno-Oncology	Cancer Vaccines	Emerging Technologies	Tackling Antimicrobial Resistance
	Development and validation of biomarkers for	Should each patient's immune system inform their immunotherapy?	Innovating vaccine development in space Rachel Clemens,	How are pharmaceutical companies contributing



## Main Agenda

	<p>diagnosis and prediction of response resistance to treatment</p> <p>Dr Ignacio Wistuba, Professor &amp; Chair, Department of Translational Molecular Pathology, MD Anderson Cancer Center</p>	<p>Dr Tom Davis, CMO, Genocea</p>	<p>Commercial Innovation Manager, International Space Station US National Laboratory</p>	<p>to the fight against antibiotic resistance with the use of vaccines</p> <p>Dr Jan Poolman, Head Bacterial Vaccine Discovery and Early Development, Janssen</p> <p>Dr Leonard Friedland, Vice President, Scientific Affairs and Public Health Vaccines, North America, GSK</p> <p>Julia Spencer, Associate Vice President, Global Vaccine Public Policy, Partnerships, Merck</p> <p>Timothy Cooke, CEO and Board member, Novadigm Therapeutics</p> <p>Dr James Wassil, Vice President and GH&amp;V BU Head, Vaccines, Pfizer</p>
12.10	<p>Intralesional IL12 enhances anti-PD-1 immune response in treatment-refractory solid tumors</p> <p>Dr David Canton, Director, R&amp;D and Clinical Science, OncoSec</p>	<p>An integrated machine-learning approach to improve the prediction of clinically relevant neoantigens</p> <p>Dr Trevor Clancy, Chief Scientific Officer, NEC Oncolmmunity AS</p>	<p>RosettaAntibodyDesign - a platform for computational antibody design</p> <p>Dr Roland Dunbrack, Professor, Molecular Therapeutics Program, Fox Chase Cancer Center</p>	
12.40	<p>Determinants of clinical response to CAR-T therapy</p> <p>Dr Francesca Milletti, Associate Director Translational Medicine, Kite, a Gilead Company</p>	<p>Artificial Intelligence to the rescue: towards personalized, neoantigen-targeted immunotherapeutics</p> <p>Dr Raphael Rousseau, EVP, Head of Product Development, CMO, Gritstone Oncology</p>	<p>Introducing a new bioparticle platform; design, polyvalence, production and immunomodulatory potential</p> <p>Louis-Philippe Vézina, PhD, CEO, Angany Inc.</p>	<p>Update on the development and use of a single-dose live oral cholera vaccine</p> <p>Dr Sean Bennett, Senior Director, Clinical Development and Medical Affairs, Emergent BioSolutions</p>
12:55			<p>Development of EcoCRM®, a new GMP CRM197 carrier protein</p> <p>Dr Andrew Lees, Scientific Director, Fina Biosolutions LLC</p>	
1.10	<p><b>Networking lunch and poster session</b></p> <p><i>Innovation &amp; Start up Zone – meet emerging biotechs and discover their innovative platforms and novel technologies in the vaccine &amp; immunotherapy space. Taking place in the exhibition area. Start-up companies include; <a href="#">Meissa Vaccines</a>, <a href="#">Inflammatix</a>, <a href="#">BioGraph 55</a>, <a href="#">Avalia Immunotherapies</a>, <a href="#">StoneStable Inc.</a>, <a href="#">InterVen Biosciences</a></i></p>			
2.10	<p>Understanding the prognostic and predictive value of hyaluronan in the TME</p> <p><i>Invited: Dr Jean-Marie Bruey, Executive Director Translational</i></p>	<p>A paradigm shift: Cancer therapy with peptide-based B-cell epitopes and peptide immunotherapeutics targeting multiple solid tumor types</p>	<p>Targeting highly conserved influenza virus epitopes with self-assembled peptides</p> <p>Dr Chris Clegg, President, Founder &amp; CSO, TRIA Bioscience</p>	<p>Development of a bioconjugate vaccine against E. coli</p> <p>Dr Jan Poolman, Head Bacterial Vaccine Discovery and Early Development, Janssen</p>

## Main Agenda

2:25	<i>Medicine - Clinical Development, Halozyme Therapeutics</i>	Dr Pravin Kaumaya, Professor, Director, Div. Vaccine Res & Peptide/Protein Engineering laboratory, The Ohio State University College of Medicine	High yield, high purity cell separation and concentration with an automated microfluidic-based system Kyle Smith, PhD Director, Research and Development, Micromedicine	
2.40	Decoding cell-free biomarker patterns to optimize the next generation of precision immunotherapies Dr Jimmy Linn, CSO Freenome	Pfizer's vaccine immunotherapy combination regimen for cancer Dr Robert Hollingsworth, Vice President & CSO Cancer Vaccines, Pfizer	Vaccine development in Chikungunya, a severe disease with debilitating long-term effects and global outbreak potential Alexander Kort, Senior Vice President Corporate Development, Themis Bioscience GmbH Themis	Prophylactic and therapeutic vaccine approach targeting C. difficile infection and relapse Kevin Killeen, Chief Scientific Officer, Matrivax
3.10	<b>Infectious Diseases</b> Overview of Immune Epitope Database Dr Biol. Sci. Alex Sette Center Head, Division Head, and Professor, Center for Infectious Disease, La Jolla Institute for Immunology	<b>Oncolytic Viruses</b> Panel: Novel approaches for the delivery of oncolytic viruses and genes Dr Evanthia Galanis, Chair Molecular Medicine, Professor of Oncology, Mayo Clinic Dr Karen Aboody, Professor, Department of Developmental & Stem Cell Biology and Division of Neurosurgery, City of Hope; Founder & CSO, Thera Biologics <i>Additional speaker TBC*</i>	Peptide-Based checkpoint receptor inhibitors as adjuvants and therapeutics in infectious diseases Dr Timothy W Phares, Head of Immunology, Explorations in Global Health (ExGloH), Leidos	Toxoid Based Multivalent Vaccine for Methicillin-Resistant Staphylococcus Aureus Javad M. Aman, President and CSO, Integrated Biotherapeutics
3.25			Engineering vaccine antigens to recruit CD4 T cell memory for enhanced antibody responses Lenny Moise, Director of Vaccine Research, EpiVax Inc	
3.40	Susceptible or Immune? A CMV T cell assay accurately predicts patient status Dr Steven Kleiboeker, Vice President, Research & Development, Viracor Eurofins BioPharma Services		Supercharging immunotherapy with novel vector technology harnessing the exceptional immunogenicity of arenaviruses Dr Anders Lilja, SVP Technical	Identification of novel mycobacterial factors involved in virulence and evasion of host immune responses in tuberculosis Dr Sangeeta Tiwari, Associate (faculty), Albert Einstein College of Medicine

## Main Agenda

			Development, HOOKIPA Pharma	
3.55	Immune monitoring assays for preclinical and clinical development		A novel chemistry platform for coupling immunogenic peptides to TLR2-agonist adjuvants to generate fully-synthetic, self-adjuvanting cancer vaccines Christa Pawlowski, Project Operations Director, SapVax LLC	
4.10	Afternoon Networking Break			
4.40	Induction of innate immunity against bacterial infection Dr Beckie Ingram, Senior Lecturer & Principal Investigator, Queens University Belfast	Immulytic; achieving personalized systemic neoantigen vaccination directly in the patient Dr Praveen Bommareddy, Translational Research Lead, Replimmune	A novel hybrid virus-like-particle technology to accelerate the conversion of antigenic epitopes into efficient immunogens deliverable as vaccines David Whitacre, Senior Vice President, VLP Biotech	<b>Controlling Highly Infectious Diseases</b> Oral Norovirus Tablet Vaccine Sean Tucker, Chief Scientific Officer & Vice President Research, Vaxart
5.10	Developing and utilizing positional scanning combinatorial libraries for T-lymphocyte antigen discovery Dr Clemencia Pinilla, Associate Member, Torrey Pines Institute for Molecular Studies	Advantages of HSV-based oncolytic virus therapies for the treatment of solid tumors Dr Andreas Niethammer, Senior Vice President, Head of Clinical Development Immunotherapy for Solid Tumors, Sorrento Therapeutics	Unique immunotherapy approach, based on an oncolytic virus non-covalently combined with tumor-specific peptides, for a highly immunogenic and rapidly adaptable tumor vaccination platform. Sari Pesonen, Vice President Scientific And Clinical Development, Co-Founder, Valo Therapeutics	Vaccinating against the poverty-related neglected diseases Dr Peter Hotez, President of the Sabin Vaccine Institute & Dean of National School of Tropical Medicine, Baylor College of Medicine
5.40	Human in vitro modeling to inform precision vaccines for	Armed and dangerous against cancer: TGF-beta	Developing multi-target single-vector vaccines and delivery	Understanding the immunology of syphilis using modern

## Main Agenda

	<p>vulnerable populations            Dr Ofer Levy, Director, Precision Vaccines Program, Boston Children's Hospital &amp; Professor, Harvard Medical School</p>	<p>trap and personalized oncolytic adenoviruses            Dr Tony Reid, CSO, EpicentRx</p>	<p>devices for Venezuelan Equine Encephalitis Virus (VEEV)            Mike Stebbins, MCDC Executive Director, Medical CBRN Defense Consortium (MCDC)</p>	<p>technology to develop a vaccine against this resurgent pathogen            Dr Juan Salazar, Executive Vice President, Connecticut Children's Medical Center</p>
6.10	<p>Chair's Closing Remarks and End of Day 1            Networking Drinks Reception</p>			

# Main Agenda

## Day 2 – Wednesday 4<sup>th</sup> December

	Clinical Development	Engaging T-Cells, Cancer Antibodies, and Combinations	Immunotherapy Bioprocessing, Manufacture & Delivery	Vaccine Development
08.30	Chairs Opening Remarks Dr Grace Chen, Deputy Chief of The Clinical Trials Program in the VRC, NIH	Chairs Opening Remarks: Dr. Steven Townson, Senior Principal Scientist, Early Oncology Development, Merck Research Laboratories	Chair's Opening Remarks	Chair's Opening Remarks Dr Kena Swanson, Director, Viral Vaccines, Pfizer Vaccine Research & Development
08.40	Vaccines early development	Combinations & Engaging T-Cells	Delivery	Vaccines Against Respiratory Diseases
	Pre-clinical toxicology considerations for vaccine development Dr Nabil Al Humadi, Pharmacologist and Toxicologist, Food and Drug Administration	Recurrent Stage 4 Cancer: A patient's journey and hope for the future Chester Kitchen, Cancer Patient Advocate	Opportunities and challenges for integrating delivery technologies into cancer immunotherapy Dr Michael J. Mitchell, Ph.D., Skirkanich Assistant Professor of Innovation, Department of Bioengineering, University of Pennsylvania	Mucosal delivery of universal flu vaccine antigens in animal models Xiaoping Zhu, Interim Associate Dean & Department Chair, University of Maryland
09.10	Novel correlates of protection against pandemic influenza Dr Aubree Gordon, Associate Professor of Epidemiology, University of Michigan	Combinations and checkpoint inhibitors; what's working? Dr Maria Karasarides, Executive Director, Immuno-Oncology, Regeneron Pharmaceuticals	Development of novel antibody-directed nanotherapeutics (ADN) for infectious diseases and cancer Dr Daryl Drummond, Head of Research, Merrimack Pharmaceuticals	Developing a single vaccine to protect against all influenza strains using ground-breaking mathematical models and research Dr Brian Price, COO, Blue Water Vaccines, Inc
09.40	The Potential Impact of a Norovirus Vaccine in the U.S. Dr Bruce Y. Lee, Professor of Health Policy and Management, City University of New York (CUNY), Exec Director of PHICOR, CEO of Symsilico, & Senior Contributor, Forbes	Versamune; a novel T-cell activating immunotherapy platform Dr Lauren Wood, CMO, PDS Biotechnology	Bioprocessing and manufacture	Broader protective influenza vaccine Naik Rumi Armaghan, Ph.D., Director and Head of Design Sciences in FluNXT, Sanofi Pasteur's "Biotech-lite"
			Engineering bispecific IgM antibodies as cancer therapeutics Dr Bruce Keyt, CSO, IGM Biosciences	

## Main Agenda

10.10	<p>Executing animal rule studies in high containment  <b>Dr Jason Comer, Assistant Professor, Department of Microbiology and Immunology, University of Texas Medical Branch at Galveston</b></p>	<p>Overcoming the immunosuppressive TME by targeting Myeloid-Derived Suppressor Cells  <b>Raymond Tesi, CEO/CMO, INmune Bio</b></p>	<p>Design &amp; manufacture of next generation biotherapeutics with a scalable biochemical protein synthesis platform  <b>Dr Maureen Bruhns, Senior Director of Analytical Development, Sutro Bio</b></p>	<p>Protection against Respiratory Syncytial Virus (RSV) by maternal immunization  <b>Kathrin Jansen, Senior Vice President of Vaccine Research and Early Development Pfizer</b></p>
10.25	<p>Using serology to support vaccine development  <b>Patrick Daugherty, CSO and Founder, Serimmune</b></p>			
10.40	Morning Networking Break			
11.30	<p><b>Interactive Roundtables</b>  <i>Interactive discussions with like-minded peers tackling the similar challenges in vaccine, antibody and immunotherapy development (Roundtables run twice each for 45mins, select two options)</i></p>			
	<p><i>Strategies to improve patient stratification by interrogating the tumor microenvironment</i>  <b>Dr Kirsteen Maclean, PhD., Associate, Scientific Director, Biomarker &amp; Translational Strategy Definiens</b></p>	<p><i>Advances in the intratumoral administration of cancer agents</i>  <b>Dr Adil Daud, Clinical Professor of Medicine, Director, Melanoma Clinical Research, UCSF Helen Diller Family Comprehensive Cancer Center</b></p>	<p><i>Single cell sequencing to understand response to vaccines and immunotherapy</i></p>	<p><i>Managing toxicity in combination immunotherapy</i>  <b>Invited: Dr Pamela Munster, Professor, Department of Medicine; Director, Early Phase Clinical Trials Unit, Co-leader of the Center for BRCA Research, UCSF Helen Diller Family Comprehensive Cancer Center</b></p>
	<p><i>Challenges in defining TMB and its relevance in different tumor types</i></p>	<p><i>Strategies of combining small molecule TKIs and immunotherapies</i>  <b>Invited: Dr Vasileios Askoxylakis, Director, Clinical Program Leader at Novartis Institutes for BioMedical Research (NIBR)</b></p>	<p><i>Generation of antibodies to novel targets</i>  <b>Dr Gary Starling, Associate Vice President, Protein Science, Merck</b></p>	<p><i>Changing landscape of real-world evidence and its impact on clinical research – uncovering lab &amp; clinical adverse events</i></p>

## Main Agenda

	<p><i>Managing process improvements for vaccines</i>  <b>Dr Justin Moran, Senior Director Bioprocess Development, Pfizer</b></p>	<p><i>Novel approaches to accelerate the discovery, development and translation of new passive and active immunization for targeted diseases</i></p>	<p><i>The road map to NIH's grant application process. How to find out more about the current programs available</i>  <b>Susan Old, Acting Deputy Director, NIAID, NIH</b></p>	<p><i>Meet the investor: your questions answered.</i>  <b>Dr Stephen Nagler, Executive Director, MedPro Investors</b>  <i>Additional investors TBC</i></p>
	<p><i>Best practices for outsourcing manufacture of biologics through CMOs</i>  <b>Dr Vadim Klyushnichenko, VP Pharmaceutical Development &amp; Quality, Calibr – a division of Scripps Research</b></p>	<p><i>Early engagement of sites: Advantages for sponsors and CROs</i>  <b>William Smith, MD, CEO, Alliance for Multispecialty Research (AMR)</b></p>	<p><i>Flavivirus vaccine – induced immune responses using mouse models</i>  <b>Dr Sujan Shresta, Associate Professor, La Jolla Institute for Immunology</b></p>	<p><i>Influenza vaccination and the diversity paradox</i>  <b>Dr Craig Thomson, CSO, Blue Water Vaccines, Inc</b></p>
1.10	<p><b>Networking Lunch and Poster session</b></p> <p><i>Innovation &amp; Start up Zone – meet emerging biotechs and discover their innovative platforms and novel technologies in the vaccine &amp; immunotherapy space. Taking place in the exhibition area. Start-up companies include; <b>Meissa Vaccines, Inflammatix, BioGraph 55, Avalia Immunotherapies, StoneStable Inc., InterVen Biosciences</b></i></p>			
2.30	<p><b>Infectious Disease Early Development &amp; Trials</b>  Exploring different Non-Human Primate models used for Tuberculosis  <b>Patricia Darrah, Staff Scientist, NIH – invited</b></p>	<p>CD40 agonists to enhance antigen presentation, resulting in improved quality and magnitude of T-cell responses  <b>Dr Ovid Trifan, CMO &amp; SVP Clinical Development, Apexigen</b></p>	<p>A plug-and-play approach to creating differentiated antibody drug candidates</p>	<p>A novel live attenuated RSV vaccine  <b>Dr Martin Moore, Co-Founder &amp; CEO, Meissa Vaccines</b></p>
3.00	<p>Immunologic causes and bacterial sources of reactivation TB and relapse after treatment  <b>Dr Philana Ling Lin, Associate Professor, Department of Pediatrics, University of Pittsburgh – invited</b></p>	<p>A novel WT1-targeting multivalent heteroclitic epitope immunotherapeutic: clinical update  <b>Dr Angelos Stergiou, CEO, SELLAS Life Sciences</b></p>	<p>Custom-designed linker technology to improve antibody drug conjugates  <i>Invited: <b>Dr Michael Kaufman, SVP, CMC, Mersana Therapeutics</b></i></p>	<p>RSV F and G Sequence Evolution Over the 2016-2019 RSV Seasons in the USA and its Implications in Vaccine and Anti-RSV Drug Development  <b>Dr Hong Jin, Senior Director, Fellow R&amp;D - Clinical Pharmacology &amp; Safety Sciences, AstraZeneca</b></p>

## Main Agenda

3.30	<p><b>Title TBC</b>  Max Ciarlet, Head, Early and Exploratory Clinical Development Cluster, Novartis Vaccines and Diagnostics – invited</p>	<p style="text-align: center;"><b>Antibody-based therapies</b></p> <p>Leveraging bispecific molecules for the combination immunotherapy of cancer  Dr Jon Wigginton, SVP, Clinical Development &amp; Chief Medical Officer, MacroGenics</p>	<p>Designing cutting edge vaccine and biotechnology manufacturing platforms *topic title TBC  Charles Heffernan, Member, BioPhorum Operations Group; Director, CRB</p>	<p style="text-align: center;"><b>Emerging and Re-Emerging diseases</b></p> <p>Development of a Chikungunya VLP vaccine  Sarah, Royalty Tredo, Senior Director, Emergent Biosolutions</p>
4.00	<b>Afternoon Networking Break</b>			
4.30	<p style="text-align: center;"><b>Immuno-Oncology Early Development &amp; Trials</b></p> <p>Designing Immuno-Oncology trials to maximizing clinical outcomes and chances of success  Dr Jun Tang, Senior Manager, CRI Venture Fund and Clinical Accelerator, Cancer Research Institute</p>	<p>Updates in the development of next generation BiTE immunotherapies  <i>Invited: Dr Gregory Friberg, Vice President and Therapeutic Area Head (Global Development), Amgen</i></p>	<p>Rapid manufacture and scale-up of off-the-shelf cell therapies  Dr Wen Bo Wang, SVP, Technical Operations, Fate Therapeutics</p>	<p>A natural killer T (NKT) cell adjuvanting vaccine platform induces liver-resident memory CD8+ T cells that protect against malaria  Dr William Heath, Professor, University of Melbourne, Scientific Advisor, Avalia Immunotherapies Limited</p>
5.00	<p>Clinical perspectives and conclusions in oncology  <i>Dr Julie Brahmer, Professor of Oncology, John Hopkins – invited</i></p>	<p>Developing Antibody-Drug-Conjugates to unique embryonic cancer stem cell targets  Dr Mike Schopperle, CEO &amp; Founder, CureMeta</p>	<p>Improving autologous CAR-T access and affordability  Dr Heidi Zhang, Global Head Analytical Development Cell Therapy, Juno Therapeutics, A Celgene Company (BMS)</p>	<p>A phase II trial of a live attenuated virus tetravalent dengue vaccine in healthy US adults  <i>Stephen Thomas, Deputy Commander of Operations, Walter Reed Army Institute of Research – invited</i></p>
5.30	<p>Trial Designs for Vaccine Therapies and Personalized Medicine in Oncology  Mary Redman, Associate Member, Clinical Research Division, Fred Hutchinson Cancer Research Center</p>	<p>Clinical development of next generation Antibody Drug Conjugates  Dr Nancy Whiting, Senior Vice President, Development, Seattle Genetics</p>	<p>Manufacturing operations and efficiencies for personalized mRNA vaccines  Dr Matthew Barrows, Director RNA Operations, Personalized Cancer Vaccine Manufacturing, Moderna Therapeutics *TBC</p>	<p>Development of single dose vaccines for emerging and re-emerging infectious diseases, preclinical data for Ebola, Marburg, Lassa Fever and Zika as examples  Dr Farshad Guirakhoo, CSO, GeoVax</p>
6.00	<b>Chair's closing remarks and end of day 2 Drinks reception</b>			



# Main Agenda

Day 3 – Thursday 5<sup>th</sup> December

	Clinical Development	Engineered Cancer Therapies	Vaccine delivery, bioprocessing & manufacture	Infectious Disease Antibodies
09.00	Chair's Opening Remarks	Chair's Opening Remarks	Chair's Opening Remarks	Chair's Opening Remarks
09.10	<b>Clinical Trial Analysis and Design</b> Clinical Trials in an International Setting Moderator: Dr Peter Hotez, President of the Sabin Vaccine Institute & Dean of National School of Tropical Medicine, Baylor College of Medicine	Unleashing the potential of gene therapy using the non-viral UltraCAR-T platform for hematological and solid tumors Dr Helen Sabzevari, President, Precigen	<b>Vaccine Bioprocessing &amp; Manufacture</b> Development and licensure of an Ebola vaccine Dr Risat Jannat, Director, Global Vaccines & Biologics Commercialization, Merck & Co.	Passive immunity strategies in infectious diseases Vu Truong, Chief Executive Officer and Chief Scientific Officer, Aridis Pharmaceuticals Larry Zeitlin, President, Mapp Biopharmaceutical, Inc Dr Joseph Kim, Chief Executive Officer, Inovio Pharmaceuticals
09.40	Dr Bruno Anspach, Director of Clinical Operations Latin America - vaccines, GSK Willem Hanekom, Deputy Director, TB Vaccines, Bill & Melinda Gates Foundation Jo Anne Welsch, Scientific Director, Group B Streptococcal Vaccine Project, PATH	Development of next generation allogenic CAR-T therapies	Advances in development of conjugate and multi-component vaccines Dr Krishna Prasad, Founder, Citranvi	
9:55	Experimental human challenge models used in respiratory track diseases and malaria			
10.10	Dr Jerald Sadoff, Senior Advisor Vaccine Development, Janssen Infectious Diseases and Vaccines	Non-genetically modified, multi-antigen T cell therapies with improved effectiveness over conventional CAR-T/ TCR approaches Reserved, Marker Therapeutics	A unique platform for research scale to mid-scale, host-independent biological manufacturing Alexander Koglin, PhD, Co-founder, Chief Science and Technology Officer, NTxBIO	

## Main Agenda

10.25	Site's perspective on frequent issues around vaccine trials <i>William Smith, Chief Executive Officer, Alliance for Multispecialty Research LLC</i>	A new vaccine strategy to boost T-cell therapy <i>Invited: Dr Darrell Irvine, Professor of Materials Science &amp; Engineering and Biological Engineering, Massachusetts Institute of Technology; Co-founder, Strand Therapeutics</i>	AI and its application in vaccine manufacture	
10.40	<b>Morning Networking Break</b>			
11.10	Using computational and informatics tools or toxicology and safety assessment for antibody projects	Targeting natural neoantigens through adoptive cellular therapies <i>Dr Stephen Schoenberger, Center Head; Professor Division of Developmental Immunology, LaJolla Institute for Immunology</i>	Recent innovation in vaccine manufacture <i>Invited: Dr Tony D'Amore, Vice President, Product Research and Development, Sanofi Pasteur</i>	Monoclonal antibody development against infectious diseases in pediatric populations <i>Kalpita Vora, Director, infectious disease and Vaccine Basic Research, Merck</i>
11.40	<b>Clinical Trials in Late Stages</b>	Identification of novel T-cell receptor targets and specificity profiling of TCRs tested in the clinic to develop safe & effective TCR therapies <i>Dr Hanspeter Gerber, CSO, 3T Bioscience</i>	Challenges in vaccine manufacture in LMICs <i>Dr Laskshmi Khandke, Senior Program Advisor, Center for Vaccine Innovation &amp; Access, PATH</i>	Antibody-based therapy to combat <i>Staphylococcus aureus</i> infections <i>Hasan Jafri, Senior Director, Clinical Research and Development, Infectious Disease and Vaccines, MedImmune</i>
	Drug development challenges within immune-oncology and analytical approaches to address them <i>Pralay Mukhopadhyay, Head of Late stage IO, Oncology Biometrics, AstraZeneca</i>			
12.10	Planning and executing pre-launch strategies to lead vaccines successfully to the market <i>Julie Post, Director, Late Stage Pipeline Vaccines (North America), Pfizer – invited</i>	Immuno-STAT – A novel platform for the selective modulation of antigen-specific T-cells <i>Dr John Ross, VP of Protein Therapeutics, Cue Biopharma</i>	<b>Vaccine Delivery</b>	Development of antibiotic drug conjugates <i>Wouter Hazenbos, Scientist, Genentech</i>
			VaxiPatch™ a new, unique and proprietary delivery technology that eliminates needle phobia, the cold chain and sharps waste? <i>Dr Daniel R. Henderson, Ph.D., CEO, CSO Verndari, Inc. *TBC</i>  Expanding vaccine effectiveness with needle-free delivery <i>Reserved</i>	

## Main Agenda

12.40	Real World Data to support oncology clinical trials <i>Dr William Capra, Global Head of Real-World Data, Oncology, Genentech/ Roche – invited</i>	Gamma delta T-cells: A universal, off-the-shelf immune cell therapy to treat cancer and other diseases <i>Dr Stuart Abbot, CSO, Adicet Bio, Inc</i>	Development of a versatile, single-injection vaccine formulation platform that can enhance immune response <i>Dr Eric Appel, Assistant Professor of Material Science and Engineering, Stanford University</i>	Rapid antibody development for Biodefense use
1.10	<b>Networking lunch and poster session</b> <i>Innovation &amp; Start up Zone – meet emerging biotechs and discover their innovative platforms and novel technologies in the vaccine &amp; immunotherapy space. Taking place in the exhibition area. Start-up companies include; <a href="#">Meissa Vaccines</a>, <a href="#">Inflammatix</a>, <a href="#">BioGraph 55</a>, <a href="#">Avalia Immunotherapies</a>, <a href="#">StoneStable Inc.</a>, <a href="#">InterVen Biosciences</a></i>			
<b>Day 3 Plenary Keynote Sessions</b>				
2.10	<b>Chair’s Opening Remarks</b>			
2.20	<b>Microbiome and epigenetic imprinting of immune responses to vaccination in humans</b> <i>Professor Bali Pulendran, Professor in the Department of Pathology and Laboratory Medicine, Stanford University School of Medicine</i>			
2.50	<b>What will be the impact of moving towards earlier lines of therapy in cancer?</b> <ul style="list-style-type: none"> <li>• Novel diagnostics and early detection initiatives</li> <li>• How will this change how we think about resistance?</li> <li>• What happens when we reach maximal amount of t-cell responses?</li> <li>• If immune capability decreases with subsequent lines of therapy is it a good idea to delay? Will investigational therapies preclude a patient from getting chemo?</li> <li>• Modifying the immune system to respond to immunotherapy</li> <li>• How does immunotherapy interact with radiation?</li> <li>• How will this affect drug candidate pipelines?</li> </ul> <i>Dr Ezra Cohen, Professor of Medicine, UCSD Moores Cancer Center, Co-director, San Diego Center for Precision Immunotherapy</i> <i>Dr Martina Sersch, CMO, Mustang Bio</i> <i>Dr Pamela D. Garzone, Chief Medical Officer. Calibr, a division of Scripps Research</i>			
3.50	<b>Creating a public-private partnership to advance global health</b> <i>Invited: Dr Andrin Oswald, Director, Life Science Industry Partnerships, Bill &amp; Melinda Gates Foundation</i>			
4.20	<b>Chair’s closing remarks and end of congress</b>			

## Agenda Overview

# 2019 Agenda Overview

DAY ONE - 3RD DECEMBER	DAY TWO - 4TH DECEMBER	DAY THREE - 5TH DECEMBER
<b>PLENARY SESSIONS</b>		
	PRE CLINICAL   CANCER ANTIBODIES   BIOPROCESSING & DELIVERY   EMERGING INFECTIOUS DISEASES	CLINICAL   CANCER ENGINEERED   MANUFACTURING   EMERGING INFECTIOUS DISEASES
NETWORKING BREAK	NETWORKING BREAK	NETWORKING BREAK
IMMUNE PROFILING   CANCER VACCINES   NEW VACCINE TECHNOLOGY   EMERGING INFECTIOUS DISEASES	<b>ROUNDTABLES</b>	CLINICAL   CANCER ENGINEERED   MANUFACTURING   EMERGING INFECTIOUS DISEASES
NETWORKING BREAK	NETWORKING BREAK	NETWORKING BREAK
IMMUNE PROFILING   CANCER VACCINES   NEW VACCINE TECHNOLOGY   EMERGING INFECTIOUS DISEASES	PRE CLINICAL   CANCER ANTIBODIES   BIOPROCESSING & DELIVERY   EMERGING INFECTIOUS DISEASES	<b>PLENARY SESSIONS</b>
NETWORKING BREAK	NETWORKING BREAK	
		<b>CLOSE OF CONGRESS</b>

The 3rd World Vaccine & Immunotherapy Congress will take place  
**December 3 – 5 in San Francisco, 2019**

Please contact [Lauren.Sheppard@terrapinn.com](mailto:Lauren.Sheppard@terrapinn.com)  
 & [Elena.Dimitriou@terrapinn.com](mailto:Elena.Dimitriou@terrapinn.com)  
 for 2019 speaking opportunities.

Organised by



# Floorplan



December 3rd-5th 2019,  
San Francisco Airport Marriott Waterfront



STAND	COMPANY
12	Aldevron
3	Alliance for Multispecialty Research
9	Avanti Polar Lipids
7	Benchling
1	BioMARC
24	Caprion Biosciences
14	Emergent Biosolutions
15	IIT Research Institute
11	Mabtech
20	MicroMedicine
4	NEOMED LABS
26	Phoseon Technology
16	Platinum Research Network
25	Universal Stabilization Technologies, Inc
10	UTMB
8	Vibalogics
17	Viracor Eurofins